ALKERMES | ALKS - Debt


ALKERMES reported $71.6M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Acadia Pharmaceuticals USD 54.81M 1.48M Sep/2025
ALKERMES USD 71.6M 1.08M Sep/2025
Amgen USD 54.59B 1.62B Sep/2025
Biogen USD 6.29B 1.7M Dec/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Gilead Sciences USD 24.94B 5M Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
J&J USD 45.8B 4.97B Sep/2025
Malin Corporation EUR 100K 0 Dec/2023
Merck USD 41.37B 5.97B Sep/2025
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
Otsuka Holdings JPY 211.51B 41.2B Jun/2025
Ovoca Bio EUR 0 0 Jun/2021
Pfizer USD 60.85B 78M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025